TransCode Therapeutics, Inc. filed a Form S-8 registration statement with the SEC on November 16, 2026, registering 1,949,894 additional shares of common stock under its 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan.

Key Highlights

  • Total shares registered: 1,949,894 additional shares of common stock across two employee benefit plans.
  • 2021 Plan allocation: 1,949,890 shares registered under the TransCode Therapeutics, Inc. 2021 Stock Option and Incentive Plan, as amended.
  • 2021 ESPP allocation: 4 shares registered under the TransCode Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
  • Automatic increase mechanism: Both plans include automatic annual share increase provisions effective January 1 of each year from 2023 through 2026, adjusted to reflect reverse stock splits.
  • Prior registrations incorporated: The filing incorporates by reference prior Form S-8 registration statements filed June 9, 2022 (No. 333-265496) and July 13, 2021 (No. 333-257868).
  • Company classification: The registrant is identified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.

TransCode Therapeutics Adds Shares to Equity Plans via S-8 Filing

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a Delaware-incorporated company headquartered at 6 Liberty Square, Boston, MA, filed a Form S-8 registration statement on November 16, 2026, to register 1,949,894 additional shares of common stock under two existing employee benefit plans. According to the filing, 1,949,890 of those shares are attributed to the 2021 Stock Option and Incentive Plan, as amended, while the remaining 4 shares are attributed to the 2021 Employee Stock Purchase Plan.

The filing states that the additional shares result from the operation of automatic annual increase provisions under both plans, applied on January 1 of each year from 2023 through 2026, and adjusted to reflect reverse stock splits pursuant to the respective plan terms. The 2021 Plan's automatic increase adds shares equal to the lesser of 5% of outstanding shares on the immediately preceding December 31 or such lesser amount as determined by the compensation committee of the company's board of directors. The 2021 ESPP's automatic increase adds shares equal to the least of 1% of outstanding shares on the immediately preceding December 31, 90,000 shares (as adjusted for reverse stock splits), or such amount as determined by the plan administrator.

The registrant incorporated by reference the contents of its prior Form S-8 filings (Registration Nos. 333-265496 and 333-257868), its Annual Report on Form 10-K for the year ended December 31, 2025 (filed April 15, 2026, and amended April 30, 2026), and all other reports filed pursuant to Sections 13(a) or 15(d) of the Exchange Act since December 31, 2025. Philippe P. Calais, Chief Executive Officer, is identified as the agent for service, and legal counsel is listed as Goodwin Procter LLP.

What Was Disclosed

TransCode Therapeutics filed a Form S-8 on November 16, 2026, registering 1,949,894 additional common shares under its 2021 Stock Option and Incentive Plan (1,949,890 shares) and 2021 Employee Stock Purchase Plan (4 shares), reflecting automatic annual increases adjusted for reverse stock splits.